{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:35:28Z","timestamp":1790253328453,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminoncol.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1053\/j.seminoncol.2016.10.008","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T13:54:35Z","timestamp":1479304475000},"page":"682-689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival"],"prefix":"10.1053","volume":"43","author":[{"given":"Dickran","family":"Kazandjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2016.10.008_bib1","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cyto.b.21273","article-title":"Better therapy requires better response evaluation: paving the way for minimal residual disease testing for every myeloma patient","volume":"90","author":"Landgren","year":"2016","journal-title":"Cytometry Clin Cytometry"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib4","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis","author":"Munshi","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib5","doi-asserted-by":"crossref","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-e346.","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib6","unstructured":"FDA Thalidomide Drug Label (United States Prescribing Information). Accessed 10\/13\/2016, at https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=2eda833b-1357-4ed4-a093-194524fcb061."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib7","unstructured":"FDA Lenalidomide Drug Label (United States Prescribing Information). Accessed 10\/13\/2016, at https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib8","unstructured":"EMA Thalidomide Drug Label (EPAR Poduct Information). Accessed 10\/13\/2016, at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000823\/WC500037050.pdf."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib9","unstructured":"EMA Lenalidomide Drug Label (EPAR Poduct Information). Accessed 10\/13\/2016, at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000717\/WC500056018.pdf."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib10","unstructured":"EMA Pomalidomide Drug Label (EPAR Poduct Information). Accessed 10\/13\/2016, at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002682\/WC500147717.pdf."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib11","unstructured":"FDA Pomalidomide Drug Label (United States Prescribing Information). Accessed 10\/13\/2016, at https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib12","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib13","unstructured":"FDA Bortezomib Drug Label (United States Prescribing Information). Accessed 10\/13\/2016, at https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib14","unstructured":"EMA Bortezomib Drug Label (EPAR Poduct Information). Accessed 10\/13\/2016, at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000539\/WC500048471.pdf."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib15","unstructured":"FDA Carfilzomib Drug Label (United States Prescribing Information). Accessed 10\/13\/2016, at https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=ea66eb30-e665-4693-99a1-a9d3b4bbe2d6."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib17","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib18","unstructured":"EMA Carfilzomib Drug Label (EPAR Poduct Information). Accessed 10\/13\/2016, at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003790\/WC500197692.pdf."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib19","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib20","unstructured":"Positive opinion on the marketing authorisation for Ninlaro (ixazomib): outcome of re-examination. 9\/16\/2016. Accessed 10\/13\/2016, at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/2016\/09\/WC500212895.pdf."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib21","unstructured":"FDA Panobinostat Drug Label (United States Prescribing Information). Accessed 10\/13\/2016, at https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7774972a-eeaa-4b9a-9e56-3fc1b968e86a."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib22","doi-asserted-by":"crossref","unstructured":"San-Miguel JF, Hungria VTM, Yoon S-S, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014;15:1195-1206.","DOI":"10.1016\/S1470-2045(14)70440-1"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib23","unstructured":"Summary Minutes of the Oncologic Drugs Advisory Committee Meeting. 11\/6\/2014. Accessed 10\/13\/2016, at http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM430826.pdf."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib24","unstructured":"FDA. FDA News Release: FDA approves Farydak for treatment of multiple myeloma. 2\/23\/2015."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib25","unstructured":"Panobinostat drug label. Accessed 10\/13\/2016, at https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7774972a-eeaa-4b9a-9e56-3fc1b968e86a."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib26","unstructured":"EMA Panobinstat Drug Label (EPAR Poduct Information). Accessed 10\/13\/2016, at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003725\/WC500193298.pdf."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib27","unstructured":"FDA Daratumumab Drug Label (United States Prescribing Information). Accessed 10\/13\/2016, at https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a4d0efe9-5e54-467e-9eb4-56fa7d53b60b."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib28","unstructured":"EMA Daratumumab Drug Label (EPAR Poduct Information). Accessed 10\/13\/2016, at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004077\/WC500207296.pdf."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib29","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib30","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib31","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib33","unstructured":"FDA Elotuzumab Drug Label (United States Prescribing Information). (Accessed 10\/13\/2016, at https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=80686b7e-f6f4-4154-b5c0-c846425e2d91.)"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib34","unstructured":"EMA Elotuzumab Drug Label (EPAR Poduct Information). Accessed 10\/13\/2016, at http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003967\/WC500206673.pdf."},{"key":"10.1053\/j.seminoncol.2016.10.008_bib35","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1634\/theoncologist.2016-0101","article-title":"Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib36","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib37","first-page":"8011","article-title":"Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma","volume":"34","author":"Moreau","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib38","first-page":"8032","article-title":"Phase I venetoclax monotherapy for relapsed\/refractory multiple myeloma","volume":"34","author":"Kumar","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib39","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib40","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","article-title":"Targeting the BRAF V600E mutation in multiple myeloma","volume":"3","author":"Andrulis","year":"2013","journal-title":"Cancer Disc"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib41","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cellsig.2012.09.008","article-title":"BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-\u03baB","volume":"25","author":"Rushworth","year":"2013","journal-title":"Cell Signal"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib42","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood.V124.21.31.31","article-title":"Ibrutinib, single agent or in combination with dexamethasone, in patients with relapsed or relapsed\/refractory multiple myeloma (MM): preliminary phase 2 results","volume":"124","author":"Vij","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib44","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1038\/bcj.2015.7","article-title":"Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients","volume":"5","author":"Yousef","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib45","doi-asserted-by":"crossref","first-page":"e0139867","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 Expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","volume":"10","author":"Sponaas","year":"2015","journal-title":"PloS One"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib46","first-page":"8010","article-title":"Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed\/refractory multiple myeloma (RRMM): final efficacy and safety analysis","volume":"34","author":"Mateos","year":"2016","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib47","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ccr.2013.02.026","article-title":"A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo","volume":"23","author":"Veitonmaki","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib48","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood.V120.21.449.449","article-title":"The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: results from a phase 2 study","volume":"120","author":"Shah","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib49","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","article-title":"Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2016.10.008_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-016-0304-z","article-title":"Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors","volume":"9","author":"Turner","year":"2016","journal-title":"J Heamtol Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377541630094X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377541630094X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T09:36:42Z","timestamp":1601199402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377541630094X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S009377541630094X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.10.008","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}